Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kashif Bhutto

Pulmonary Disease Belleville, IL Medical Doctor

NPI 1083791651 CMS profile 94115

4600 Memorial Dr Ste 200, Belleville, IL 62226

Open in the dashboard

General payments

$19,467

736 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kashif Bhutto of Belleville, IL is reported in the CMS Open Payments database as having received $19,467 across 736 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,346 44
2024 General $2,636 129
2023 General $2,359 115
2022 General $2,480 104
2021 General $1,893 100
2020 General $1,480 90
2019 General $2,272 154

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kashif Bhutto
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Kashif Bhutto were reported at $6,346. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Kashif Bhutto Pulmonary Disease median Middle half National median
2019 $2,272 $377 $109–$1,340 $163
2020 $1,480 $230 $56–$907 $114
2021 $1,893 $269 $68–$1,072 $132
2022 $2,480 $390 $100–$1,457 $149
2023 $2,359 $419 $114–$1,659 $160
2024 $2,636 $476 $123–$1,818 $164
2025 $6,346 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $5,389 9 payments
  2. AstraZeneca Pharmaceuticals LP $2,608 120 payments
  3. GlaxoSmithKline, LLC. $2,068 142 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $1,499 90 payments
  5. Olympus Corporation of the Americas $983 9 payments
  6. Insmed, Inc. $936 42 payments
  7. Genzyme Corporation $732 31 payments
  8. Regeneron Healthcare Solutions, Inc. $592 23 payments
  9. Grifols USA, LLC $437 22 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $420 17 payments
  11. Other $3,801 231 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,885 713 payments
  2. Education $4,263 9 payments
  3. Travel and Lodging $2,318 14 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $5,389 9 payments
  2. BREZTRI $1,296 48 payments
  3. TRELEGY ELLIPTA $1,123 82 payments
  4. Arikayce $936 42 payments
  5. DUPIXENT Immunology $813 33 payments
  6. FASENRA $804 21 payments
  7. OFEV $723 42 payments
  8. GLASSIA $539 28 payments
  9. DUPIXENT Inflammation And Immunology $524 21 payments
  10. SYMBICORT $499 19 payments
  11. Other $8,739 454 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

4,797

Median for Pulmonary Disease: 936

Drug cost

$1,570,827

Median for Pulmonary Disease: $487,987

Branded share of claims

71.4%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 555 $496,372
Breo Ellipta Fluticasone/Vilanterol Brand 380 $214,447
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 269 $164,867
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 155 $113,022
Spiriva Respimat Tiotropium Bromide Brand 136 $89,501
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 165 $85,224
Aralast Np Alpha-1-Proteinase Inhibitor Brand 17 $59,851
Tezspire Tezepelumab-Ekko Brand 12 $53,199
Ambrisentan Generic 13 $37,652
Symbicort Budesonide/Formoterol Fumarate Brand 100 $34,548

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$144,539

Of which drugs: $1,541

Medicare patients

710

Average age 75

Services billed

2,325

414 women, 296 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 64%
Ischemic heart disease 61%
Arthritis 59%
Chronic kidney disease 43%
Heart failure 42%
Diabetes 39%
Depression 31%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 15 15 $1,227

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$383 — —
BREZTRI
$231 155 —
OFEV
$197 — —
AREXVY
$187 — —
Arikayce
$176 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

736 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record